2018 Oncology Annual Meeting Phase III Trial Data You Can’t Miss

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting begins tomorrow at the McCormick Place Convention Center in Chicago, Illinois. More than 39,000 participants from around the world are expected to attend this meeting to share the latest advances in cutting edge oncology research and patient care over the next five days. The theme of this year’s meeting, chosen by current ASCO president Bruce Johnson, MD (Dana-Farber Cancer Institute, Boston, Massachusetts), is “Delivering Discoveries: Expanding the Reach of Precision Medicine,” highlighting the role of precision medicine in advancing innovative treatment options for patients with cancer. This theme is reflected in the many of the 2,525 scientific abstracts that will be presented during oral sessions, clinical science symposia, and poster sessions. As in recent years, immunotherapy continues to take center stage at the meeting.

The prIME Lines team has identified 15 abstracts of phase III trials across various tumor types that may have the potential to impact clinical practice. Please stay tuned throughout the summer as we bring you comprehensive coverage from the ASCO Annual Meeting.

Breast Cancer

  • Abstract #LBA1TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score | Plenary Session: Sunday, June 3 from 1.00 PM to 4.00 PM, Hall B1
  • Abstract #506—PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.  | Breast Cancer—Local/Regional/Adjuvant: Monday, June 4 from 8.00 AM to 11.00 AM, Hall D2
  • Abstract #1000—Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3. | Breast Cancer—Metastatic: Sunday, June 3 from 8.00 AM to 11.00 AM, Hall D2
  • Abstract #LBA1006—Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. | Breast Cancer—Metastatic: Sunday, June 3 from 8.00 AM to 11.00 AM, Hall D2

Gastrointestinal Cancers

  • Abstract #LBA4001—Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. | Gastrointestinal (Noncolorectal) Cancer: Monday, June 4 from 15.00 PM to 18.00 PM, Arie Crown Theater
  • Abstract #LBA4002­—Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1) : A randomized, controlled, multicenter phase III trial. | Gastrointestinal (Noncolorectal) Cancer: Monday, June 4 from 15.00 PM to 18.00 PM, Arie Crown Theater

Genitourinary Cancer

  • Abstract LBA3—CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. Plenary Session: Sunday, June 3 from 1.00 PM to 4.00 PM, Hall B1

Lung Cancer

  • Abstract LBA4—Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Plenary Session: Sunday, June 3 from 1.00 PM to 4.00 PM, Hall B1
  • Abstract LBA9000—IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.| Lung Cancer—Non-Small Cell Metastatic: Monday, June 4 from 15.00 PM to 18.00 PM, Hall B1
  • Abstract 105—Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). | Clinical Science Symposium—Sunday, June 3 from 9.45 AM to 11.15 AM, Hall D1
  • Abstract 9002—Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. | Lung Cancer—Non-Small Cell Metastatic: Monday, June 4 from 15.00 PM to 18.00 PM, Hall B1
  • Abstract 9004—Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis. | Lung Cancer—Non-Small Cell Metastatic: Monday, June 4 from 15.00 PM to 18.00 PM, Hall B1

Melanoma

  • Abstract 9504—Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. | Melanoma: Monday, June 4 from 8.00 AM to 11.00 AM, Arie Crown Theater)

Hematologic Malignancies

  • Abstract 8001—Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.| Hematologic Malignancies—Plasma Cell Dyscrasia: Friday, June 1 from 14.45 PM to 17.45 PM, E450
  • Abstract 8000—Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W. | Hematologic Malignancies—Plasma Cell Dyscrasia: Friday, June 1 from 14.45 PM to 17.45 PM, E450

preview-of-ASCO-2018